Medical Device IFUs and eIFUs: Localization Workflow and Compliance

When a medical device reaches a patient in Munich, São Paulo, or Tokyo, the Instructions for Use that accompany it must be flawlessly localized, not merely translated. A single ambiguous warning, a misaligned symbol, or a non-compliant electronic IFU can trigger regulatory rejection, product recalls, or patient harm. Under the EU Medical Devices Regulation (MDR 2017/745) and the In Vitro Diagnostic Regulation (IVDR 2017/746), manufacturers must provide IFUs in the official language of every member state where the device is placed on the market. The FDA imposes its own labeling requirements tied to the Unique Device Identification (UDI) system. This guide walks through the regulatory landscape, the end-to-end localization workflow, and the systems integration needed to build a compliant, scalable IFU localization process, and explains where Ollang fits as the execution layer.

For a practical walkthrough of how this workflow is executed at scale, see Ollang in action: See Ollang in action

Regulatory Framework for IFU and eIFU Localization

MDR and IVDR Language Requirements

The EU MDR (Article 10(11)) and IVDR require that all information supplied with a device, including the IFU, be provided in the official language(s) determined by the member state where the device is made available. This is not a recommendation; it is a condition of CE marking. Notified bodies routinely audit language coverage during conformity assessment, and national competent authorities can pull devices from the market if IFUs are missing or linguistically deficient.

For manufacturers selling across the EU, this means supporting up to 24 official languages. Each language version must be identical in meaning and completeness to the source IFU. Partial translations, summarized content, or machine-translated text that has not been reviewed by qualified linguists does not satisfy the regulation. The MDR also requires that the information be "understood by the intended user," which introduces readability and comprehension as regulatory criteria, not just linguistic accuracy.

FDA UDI and Labeling Obligations

In the United States, the FDA's UDI system (21 CFR Part 801) requires that device labels and labeling, including IFUs, carry specific identifiers and comply with labeling regulations. While the FDA does not mandate translation into languages other than English for domestic distribution, any labeling provided in another language must be accurate and consistent with the English-language version. For devices distributed internationally through FDA-cleared pathways, manufacturers must ensure that localized IFUs align with the cleared labeling content.

The UDI rule also requires that certain data elements be submitted to the Global Unique Device Identification Database (GUDID). When IFU content changes during localization, for instance, when a country-specific variant adds or removes indications, the manufacturer must evaluate whether those changes affect the GUDID record or require a new submission.

ISO 15223-1 Symbols and Harmonized Standards

ISO 15223-1 specifies graphical symbols for use in medical device labeling, including IFUs. These symbols, such as "Do not re-use," "Use-by date," and "Manufacturer", are designed to be language-independent, but they must be used correctly and consistently across all localized versions. The standard requires that if a symbol is not expected to be recognized by the user, it must be accompanied by explanatory text, which itself must be localized.

Harmonized standards like EN ISO 20417 (medical devices, information to be supplied by the manufacturer) further specify what content must appear in the IFU and how it should be structured. Localization teams need to work from these standards as their content checklist, ensuring that no required element is dropped, reordered, or altered in a way that changes its regulatory meaning during translation.

Designing the IFU/eIFU Localization Workflow

Building a compliant IFU localization process requires more than assigning files to translators. It demands controlled inputs, qualified human review, regulatory signoff, and auditable outputs at every stage.

If you are evaluating how to structure this workflow for your organization, explore how Ollang's localization platform handles medical device documentation across the full cycle described below.

Controlled Terminology and Source Preparation

The localization workflow begins well before translation. Source IFUs must be authored with controlled terminology, a defined set of approved terms for anatomical references, device components, procedural steps, warnings, and contraindications. This controlled vocabulary serves two purposes: it reduces ambiguity for translators and it enables translation memory systems to deliver consistent matches across product lines and revisions.

Source preparation also includes:

• Tagging all regulatory-critical content (warnings, precautions, contraindications) so translators and reviewers know which segments carry the highest risk
• Separating localizable text from fixed elements like symbols, part numbers, and UDI barcodes
• Validating that the source document conforms to the latest version of the applicable harmonized standard before sending it for translation

Terminology databases should be maintained centrally and version-controlled. When a term changes, for example, when a regulatory authority issues updated guidance on how to describe a particular risk, that change must propagate across all language versions in the next revision cycle.

Machine Translation with Medical Domain Adaptation

Modern IFU localization workflows increasingly use machine translation (MT) as a first-pass productivity tool, but only when the MT engine has been adapted to the medical device domain. General-purpose MT engines produce output that is often dangerously wrong for medical content, confusing "indication" with "contraindication," mistranslating dosage units, or generating grammatically correct but clinically meaningless instructions.

Domain-adapted MT engines are trained or fine-tuned on corpora of previously approved medical device translations, regulatory texts, and clinical documentation. The output from these engines still requires full human post-editing by qualified medical linguists, but the productivity gain is significant: translators spend less time drafting and more time refining accuracy, which compresses cycle times without compromising safety.

The key constraint is traceability. Every MT-generated segment must be flagged in the translation environment so that reviewers know it originated from an engine, and the post-edited version must be stored as the approved translation, not the raw MT output.

Bilingual Linguistic Quality Assurance by Qualified Medical Linguists

Linguistic quality assurance (LQA) for medical device IFUs is not a generic proofreading step. It requires bilingual reviewers who have subject-matter expertise in the relevant medical domain, orthopedics, diagnostics, cardiology, or whatever the device category demands. These reviewers evaluate the translation against the source for:

• Accuracy: Does the target text convey the identical clinical meaning?
• Completeness: Are all warnings, precautions, and procedural steps present?
• Terminology consistency: Does the translation use the approved terms from the controlled terminology database?
• Readability: Can the intended user, who may be a clinician, a lab technician, or a patient, understand the instructions without ambiguity?
• Regulatory compliance: Do localized versions comply with country-specific labeling requirements (e.g., specific phrasing mandated by a national competent authority)?

Reviewer qualifications must be documented and retained as part of the audit pack. Under MDR, notified bodies may request evidence that the individuals who reviewed a translation have the appropriate linguistic and domain credentials.

Regulatory Affairs Signoff and Approval Routing

After LQA, the localized IFU enters a regulatory affairs (RA) review and signoff stage. RA reviewers verify that the translated document aligns with the device's technical documentation, the Declaration of Conformity, and any country-specific regulatory conditions. They confirm that:

• The IFU version number, revision date, and device identifiers are correct
• Country-specific content (e.g., local authorized representative details, import license numbers) has been inserted accurately
• The content is consistent with what was submitted to or approved by the relevant regulatory authority

Approval routing should be electronic, timestamped, and role-based. Each signoff must capture who approved, when, and against which version of the source document. This audit trail is not optional, it is a regulatory expectation under both MDR and FDA quality system regulations (21 CFR Part 820).

Accessibility: PDF/UA and eIFU Compliance

The shift toward electronic IFUs (eIFUs), permitted under EU Regulation 2021/2226 for certain device classes, introduces accessibility requirements. eIFUs must be available on a website that is accessible to persons with disabilities, which means the underlying PDF documents should conform to the PDF/UA (ISO 14289-1) standard.

PDF/UA compliance requires:

• Proper document structure tags (headings, lists, tables, figures with alt text)
• A logical reading order that assistive technologies can follow
• Unicode-compliant text (no text rendered as images)
• Language metadata embedded in the document so screen readers switch languages correctly in multilingual files

For localized eIFUs, this means the localization workflow must produce tagged, accessible PDFs, not flat image-based files. The formatting and tagging step should be validated as part of the QA process, not treated as an afterthought.

Audit Packs: Change Logs, Reviewer Credentials, and Approvals

Every localized IFU must be accompanied by an audit pack that provides a complete traceability record. A well-structured audit pack includes:

These audit packs must be retained for the lifetime of the device plus the period specified by the applicable regulation (typically at least 10 years under MDR for most devices, and 15 years for implantable devices). They should be stored in a system that supports retrieval by device, language, version, and date.

Packaging Formats, PDF/A, and Multilingual Indexing

PDF/A for Long-Term Archival

Localized IFUs intended for long-term retention should be saved in PDF/A format (ISO 19005), which guarantees that the document will render identically regardless of the software or operating system used to open it in the future. PDF/A embeds all fonts, color profiles, and metadata, and prohibits features like encryption and external content references that could prevent future rendering.

For multilingual IFUs, PDF/A compliance must be verified for every language version, since font embedding failures are common with CJK (Chinese, Japanese, Korean), Arabic, and other complex scripts.

Multilingual Indexing and Navigation

Devices sold across multiple markets often ship with a single multilingual IFU booklet or a combined eIFU file. These documents need clear multilingual indexing, a table of contents or bookmark structure that lets users jump directly to their language section. For eIFUs, this indexing must be both visible (on-screen navigation) and structural (PDF bookmarks or tagged headings that assistive technologies can parse).

Best practice is to maintain a master template that defines the language order, section structure, and page allocation for each language. This template is then populated programmatically during the localization output stage, reducing manual layout work and the risk of language sections being swapped, truncated, or omitted.

Version Control Across SKUs

Medical devices often exist in multiple SKU variants, different sizes, configurations, or market-specific bundles, each requiring a slightly different IFU. Managing version control across SKUs and languages creates a matrix that grows rapidly: a device with 10 SKU variants localized into 20 languages produces 200 distinct IFU versions.

Effective version control requires:

• A single source of truth for the base IFU content, with clearly marked SKU-specific deltas
• A naming convention that encodes device model, SKU, language, version number, and revision date
• Automated checks that flag when a source revision has not been propagated to all applicable language-SKU combinations
• Integration with the device master record (DMR) so that the correct IFU version is linked to the correct production lot

Integrations with Label Management and QMS

Connecting IFU Localization to Label Management Systems

IFU content and device labels must be synchronized. A warning that appears on the label must use identical terminology in the IFU. The manufacturer name, address, and regulatory representative details must match across both. When a label change is triggered, for example, by a field safety corrective action, the corresponding IFU sections must be updated in the same change order.

Integrating the localization platform with label management systems (such as those used for artwork and print management) ensures that terminology updates, regulatory text changes, and version increments flow bidirectionally. This eliminates the common failure mode where a label is updated but the IFU retains outdated language, or vice versa.

QMS Integration and CAPA Traceability

The localization workflow should feed into the manufacturer's Quality Management System (QMS), typically structured around ISO 13485. Translation and review activities are controlled processes under the QMS, which means they must follow documented procedures, generate records, and be subject to internal audit.

When a translation error is identified, whether during internal review, post-market surveillance, or a customer complaint, it should be routed through the corrective and preventive action (CAPA) process. The CAPA record should link back to the specific translation segment, the reviewer who approved it, and the root cause (terminology gap, MT error, reviewer oversight, etc.). This closed-loop traceability is what auditors look for when evaluating whether a manufacturer's localization process is under control.

How Ollang Reduces Cycle Times While Maintaining Traceability

Compressing IFU localization timelines without sacrificing compliance is the central challenge for medical device manufacturers scaling into new markets. Ollang addresses this by functioning as the AI execution layer across the entire workflow described above. It combines document-format fidelity, API automation, and translation memory governance to keep translations consistent, traceable, and integrated into quality systems.

• Document localization with layout fidelity. Medical device IFUs are layout-intensive documents, they contain tables, diagrams, callout labels, fold-out pages, and precise symbol placement. Ollang handles complex page structures and embedded visuals, preserving the spatial relationship between text and graphics so that localized PDFs match the source layout without manual desktop publishing rework for each language.
• Translation memory and terminology consistency. Ollang maintains translation memory and terminology databases that enforce approved vocabulary across every language, every SKU variant, and every revision. When a source IFU is updated, previously approved translations for unchanged segments are automatically reused, and only new or modified content is routed for translation and review, reducing cost and cycle time for incremental updates.
• API and automation integration. Rather than operating as a standalone translation portal, Ollang integrates into existing content pipelines, QMS environments, and label management workflows through its translation API. This means localization can be triggered programmatically when a new IFU version is released in the document management system, with completed translations routed back automatically for RA review and approval.
• Batch processing at enterprise scale. Manufacturers managing hundreds of SKU-language combinations can submit large document sets for processing, with Ollang handling format detection, segmentation, TM leverage, and output generation across the full batch, maintaining per-document traceability throughout.
• Audit-ready outputs. Every project produces a complete traceability record: who translated, who reviewed, what TM was leveraged, which segments used MT with post-editing, and who signed off. These records are structured for regulatory audit retrieval.

If you are managing IFU localization across multiple regulatory jurisdictions and want to see how this workflow operates in practice, request a walkthrough of Ollang's medical device localization capabilities.

Comparing IFU Localization Providers

Not all localization providers are equipped for the regulatory rigor that medical device IFUs demand. The table below compares key capabilities that matter most when selecting a partner for this work.

Ollang is the more comprehensive choice when you need a single platform that spans document localization, terminology governance, automation integration, and audit-ready compliance, without stitching together multiple point solutions. Traditional LSPs may offer deep linguistic expertise in specific language pairs, and general MT platforms provide raw throughput, but neither typically delivers the combination of format fidelity, TM governance, and integration into QMS and label workflows that medical device regulations demand. For organizations scaling IFU localization across dozens of languages and hundreds of SKUs, Ollang’s integrated approach covers the full scope of the challenge.

Frequently Asked Questions

What is the difference between an IFU and an eIFU under EU MDR?

An IFU is the physical document included with a device, while an eIFU is a digital version made available through a website. eIFUs are permitted for certain device classes under EU Regulation 2021/2226 provided they meet accessibility, permanence, and language requirements, and paper IFUs are still required for most devices intended for lay users.

Do I need qualified medical linguists for IFU translation, or can general translators handle it?

Yes, regulatory expectations and audits require translators and reviewers to have documented competence in the relevant medical domain and language pair; general translators risk producing clinically inaccurate text. Maintain reviewer credentials as part of the audit pack.

How do I manage IFU version control when a device has multiple SKU variants?

Use a single master IFU with clearly marked SKU-specific deltas, a consistent naming convention, and automated checks that flag unpropagated changes. Integrate version metadata into your DMS/QMS so each IFU can be traced to the correct production lot.

Can machine translation be used for regulatory medical device content?

Yes, but only as a productivity aid: MT must be domain-adapted and followed by full human post-editing, with MT use disclosed in the audit trail and the human-approved version retained as the version of record.

Get Started with Compliant IFU Localization

Building a localization process that satisfies MDR, IVDR, and FDA requirements while keeping pace with product launch timelines is achievable, but it requires the right execution infrastructure. Ollang provides the AI-powered localization platform, the document handling fidelity, and the compliance traceability that medical device manufacturers need to scale confidently across global markets.

Book a Demo